A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Atezolizumab (Primary) ; HTL 0039732 (Primary)
- Indications Bladder cancer; Cancer; Carcinoma; Cervical cancer; Colorectal cancer; Gastrointestinal cancer; Head and neck cancer; Lung cancer; Mesothelioma; Pancreatic cancer; Phaeochromocytoma; Prostate cancer; Renal cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; First in man
Most Recent Events
- 08 Jun 2025 Planned End Date changed from 1 Sep 2026 to 1 Jun 2027.
- 08 Jun 2025 Planned primary completion date changed from 1 Sep 2026 to 1 Jun 2027.
- 17 Sep 2024 Trial design were presented at the 49th European Society for Medical Oncology Congress.